The analysis by the Royal College of Paediatrics and Child Health suggests the main barriers to access are factors like ...

A new task force comprising staff from the UK medicines regulator, the MHRA, and cost-effectiveness arbiter NICE – with the ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab which achieved significant ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Galapagos announces leadership transition. European biotechnology company Galapagos completed a significant leadership ...

Hikma's announcement ties into that sentiment, coming with the strap line: "America Leans on Hikma: Quality Medicines ...

GRIN-related neurodevelopmental disorder (GRIN-NDD) is a family of rare, genetically defined neurodevelopmental disorders ...

In the case of the amyloid drugs, Eisai Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) – there are also ...

BioCryst has agreed to sell its European business based on hereditary angioedema (HAE) therapy Orladeyo to Italy's Neopharmed ...

Since the first-generation CAR-Ts reached the market several years ago, clinicians have become more adept at handling ...

It's a shot in the arm for Cambridge, Massachusetts-based Moderna as it faces an evolving regulatory environment for vaccines in the US under new Health and Human Services (HHS) Secretary Robert F ...

ASCO 2025 spotlighted new data across haematologic cancers this year. To discuss announcements in liquid cancers further, as opposed to solid tumours, pharmaphorum spoke with Dr Lore Gruenbaum, chief ...